Gut Microbiota Interaction in Glioma Progression

The expanding body of research into the gut microbiota has uncovered its profound influence on glioma progression via metabolic, immunological and neurochemical pathways. The composition of intestinal microbial communities can be altered by tumour growth, and conversely specific bacteria and their metabolites modulate the tumour microenvironment and host immune surveillance. Gut-derived short-chain fatty acids and amino acid metabolites shape the activity of microglia, macrophages and T cells within the central nervous system, thereby affecting tumour proliferation and invasion. Moreover, dysbiosis may influence blood–brain barrier integrity and the efficacy of standard therapies. Understanding these bidirectional interactions opens avenues for predictive biomarkers and novel adjuvant strategies that target microbial ecosystems to slow glioma progression and enhance therapeutic outcomes.

Research from Nature Portfolio

Recent work has demonstrated that glioma development induces significant alterations in gut microbial diversity and community structure in both murine models and human patients. Tumour-bearing mice exhibited shifts in the Firmicutes/Bacteroidetes ratio and enrichment of Akkermansia, mirroring observations in glioma patients at diagnosis. These microbial changes were independent of chemotherapy exposure, suggesting that glioma itself drives dysbiosis. The findings support the concept that tumour growth disrupts gut ecology, potentially contributing to systemic inflammation and immunosuppression. Translation of these patterns to human cohorts highlights the potential for microbial profiling as a non-invasive marker of disease progression.

Gut Microbiota Interaction in Glioma Progression publication trend

The graph below shows the total number of articles in gut microbiota interaction in glioma progression across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of microorganisms residing in the gastrointestinal tract, including bacteria, archaea and fungi, which interact with the host immune and nervous systems.

Dysbiosis: A state of disturbed microbial balance in the gut ecosystem characterised by reduced diversity or overgrowth of pathogenic species.

Gut–brain axis: The bidirectional communication network linking the gastrointestinal tract and the central nervous system via neural, hormonal and immune pathways.

Tumour microenvironment: The complex milieu surrounding cancer cells, comprising immune cells, blood vessels, signalling molecules and extracellular matrix components.

Temozolomide (TMZ): An oral alkylating chemotherapy agent commonly used as first-line treatment in glioma that exerts anti-tumour effects by inducing DNA damage.

Immune checkpoint inhibitors (ICIs): Therapeutic antibodies that block inhibitory pathways on T cells, such as PD-1/PD-L1, to reinvigorate anti-tumour immune responses.

References

1. Gut microbiota in brain tumors: An emerging crucial player. CNS Neuroscience & Therapeutics (2023).
2. Glioma and temozolomide induced alterations in gut microbiome. Scientific Reports (2020).
3. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of Translational Medicine (2023).
4. Exploring the gut microbiota and its potential as a biomarker in gliomas. Biomedicine & Pharmacotherapy (2024).
5. Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma. Frontiers in Immunology (2024).